Reducing the risk of severe complications among patients with Clostridium difficile infection

Canadian Journal of Gastroenterology

Volumn 25, Issue 7, 2011, Pages 368-372

  Manek, Kamran ^a   Williams, Victoria ^a   Callery, Sandra ^a   Daneman, Nick ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clostridium difficile; Complications; Metronidazole; Risk factors; Vancomycin

Indexed keywords

CREATININE; DIPHENOXYLATE; LOPERAMIDE; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TRANSFUSION; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLON RESECTION; CONFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL INFECTION; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION RISK; INTENSIVE CARE; INTESTINE PERFORATION; LACTOBACILLUS; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REINFECTION; RETROSPECTIVE STUDY; SACCHAROMYCES BOULARDII; TACHYCARDIA; TERTIARY HEALTH CARE; THERAPY DELAY; TOXIC MEGACOLON; COMORBIDITY; HOSPITALIZATION; MULTIVARIATE ANALYSIS; PSEUDOMEMBRANOUS COLITIS;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; COMORBIDITY; CONFUSION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; HYPOTENSION; LEUKOCYTOSIS; MALE; METRONIDAZOLE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VANCOMYCIN;

EID: 80053054887     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/153020     Document Type: Article

References (22)

1. Zoutman DE, Ford BD, Bryce E, et al. The state of infection surveillance and control in Canadian acute care hospitals. Am J Infect Control 2003;31:266-72.
2. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40.
3. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-15.
4. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009;48:568-76.
5. Ramaswamy R, Grover H, Corpuz M, et al. Prognostic criteria in Clostridium difficile colitis. Am J Gastroenterol 1996;91:460-4. (Pubitemid 26083546)
6. Nair S, Yadav D, Corpuz M, et al. Clostridium difficile colitis: Factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol 1998;93:1873-6. (Pubitemid 29071697)
7. Kyne L, Merry C, O'Connell B, et al. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 1999;28:107-13. (Pubitemid 29161213)
8. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004;38:414-8.
9. Drew RJ, Boyle B. RUWA scoring system: A novel predictive tool for the identification of patients at high risk for complications from Clostridium difficile infection. J Hosp Infect 2009;71:93-4.
10. Henrich TJ, Krakower D, Bitton A, et al. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009;15:415-22.
11. Gujja D, Friedenberg FK. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009;29:635-42.
12. Valiquette L, Pepin J, Do XV, et al. Prediction of complicated Clostridium difficile infection by pleural effusion and increased wall thickness on computed tomography. Clin Infect Dis 2009;49:554-60.
13. Provincial Infectious Diseases Advisory Committee. Best Practices Document for the Management of Clostridium difficile in all health care settings. 2009. Ontario Ministry of Health and Long Term Care. 〈http://www.health.gov.on.ca/english/providers/program/ infectious/diseases/best-prac/bp-cdiff.pdf〉 (Accessed May 2010).
14. Hintze JL. PASS 2005. NCSS, LLC. Kaysville, Utah, USA. 〈www.ncss.com〉.
15. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
16. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(Suppl 1):S81-S92.
17. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. N Engl J Med 2009;361:1368-75.
18. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7. (Pubitemid 47101025)
19. Miller M, Bernard L, Thompson M, Grima D, Pepin J. Lack of increased colonization with vancomycin-resistant Enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Inf Cont Hosp Epi 2010;31:710-5.
20. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77. (Pubitemid 46084814)
21. Hecker MT, Aron DC, Patel NP, et al. Unnecessary use of antimicrobials in hospitalized patients: Current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003;163:972-8. (Pubitemid 36519743)
22. Koo HL, Koo DC, Musher DM, et al. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009;48:598-605.